Evaluation of bayesian forecasting for individualized gentamicin dosage in infants weighing 1000 g or less.

We evaluated the use of Bayesian forecasting for gentamicin therapy in outborn infants weighing 1000 g or less irrespective of postnatal age. Dosages were individualized using a computer program, guided by early serum gentamicin assays after a loading dose and a database of population kinetics. Steady-state gentamicin levels achieved were compared with those from a regimen based on guidelines. A total of 26 gentamicin courses were individualized in 19 infants of 22 to 33 weeks' gestation, weighing 500 to 1000 g at 1 to 41 days of age. All steady-state trough levels were between 1 and 2.4 mg/L; peak levels were between 4.4 and 9.3 mg/L. The 95% confidence intervals were in almost identical ranges. The prevalence of toxic and suboptimal trough levels was less when compared with that of 23 gentamicin courses based on guidelines in 17 control infants. We conclude that early individualized gentamicin dosage over a range of postnatal age is a practical alternative and serum level distributions appear superior.

[1]  A. Provoost,et al.  Nephrotoxicity of Aminoglycosides in Young and Adult Rats , 1985, Pediatric Research.

[2]  A W Kelman,et al.  Estimation of gentamicin clearance and volume of distribution in neonates and young children. , 1984, British journal of clinical pharmacology.

[3]  DO APGAR SCORES INDICATE ASPHYXIA? , 1982, The Lancet.

[4]  R. Leake,et al.  Glomerular Filtration Rate during the Period of Adaptation to Extrauterine Life , 1977, Pediatric Research.

[5]  G. Schumacher,et al.  Bayesian approaches in pharmacokinetic decision making. , 1984, Clinical Pharmacist.

[6]  B. Arant,et al.  Pathophysiologic Evidence of Gentamicin Nephrotoxicity in Neonatal Puppies , 1980, Pediatric Research.

[7]  A W Kelman,et al.  OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics. , 1982, British journal of clinical pharmacology.

[8]  L B Sheiner,et al.  Forecasting individual pharmacokinetics , 1979, Clinical pharmacology and therapeutics.

[9]  G. Schumacher.  Pharmacokinetic Analysis of Gentamicin Dosage Regimens Recommended for Renal Impairment , 1975, Journal of clinical pharmacology.

[10]  R. Moore,et al.  The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. , 1984, The Journal of infectious diseases.

[11]  K. Rodvold,et al.  Bayesian Forecasting of Serum Gentamicin Concentrations in Intensive Care Patients , 1990, Clinical pharmacokinetics.

[12]  C. Prober,et al.  Aminoglycoside‐related nephrotoxicity in the premature newborn , 1984, Clinical pharmacology and therapeutics.

[13]  P J Huber,et al.  A Bayesian feedback method of aminoglycoside dosing , 1985, Clinical pharmacology and therapeutics.

[14]  R. Holmes,et al.  Prospective Comparative Study of Variable Dosage and Variable Frequency Regimens for Administration of Gentamicin , 1975, Antimicrobial Agents and Chemotherapy.

[15]  G. Koren,et al.  Optimization of gentamicin therapy in very low birth weight infants. , 1985, Pediatric pharmacology.

[16]  M. Barza,et al.  Why Monitor Serum Levels of Gentamicin? , 1978, Clinical pharmacokinetics.

[17]  L. S. James,et al.  Gentamicin kinetics in the neonate. , 1985, Pediatric pharmacology.

[18]  F H Derkx,et al.  Evaluation of a microcomputer program (OPT) for parameter optimisation in clinical pharmacokinetics: gentamicin and tobramycin. , 1987, British journal of clinical pharmacology.

[19]  B. Assael,et al.  Gentamicin dosage in preterm and term neonates. , 1977, Archives of disease in childhood.